Report scope. This 2026 Drug Asset Due Diligence Report evaluates Adakitug as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Adakitug is a Monoclonal antibody associated with IL-8 and a global highest development stage of Phase 2. The lead disclosed indication is Hepatocellular Carcinoma. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Adakitug
- Target: IL-8
- Lead indication: Hepatocellular Carcinoma
- Highest phase: Phase 2
- Matched trials: 12
- Matched result records: 9
- Matched asset deals: 1
Use PatSnap Life Sciences MCP servers to validate the Adakitug diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Adakitug, the MCP profile identifies IL-8 as the primary target context and Hepatocellular Carcinoma as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Adakitug diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05148234 | Phase 1/2 | Terminated | Not disclosed | Not disclosed |
| NCT04848116 | Phase 2 | Active, not recruiting | Not disclosed | Not disclosed |
| NCT04572451 | Phase 1 | Active, not recruiting | Not disclosed | Not disclosed |
| NCT04347226 | Phase 2 | Terminated | Not disclosed | Not disclosed |
| NCT04123379 | Phase 2 | Active, not recruiting | Not disclosed | Not disclosed |
| NCT04050462 | Phase 2 | Terminated | Not disclosed | Not disclosed |
| NCT03689699 | Phase 1/2 | Active, not recruiting | Not disclosed | Not disclosed |
| NCT03400332 | Phase 1/2 | Completed | Not disclosed | Not disclosed |
| NCT03026140 | Phase 2 | Recruiting | Not disclosed | Not disclosed |
| NCT02536469 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NCT02451982 | Phase 2 | Active, not recruiting | Not disclosed | Not disclosed |
| EUCTR2013-001074-15-GB | Phase 1/2 | Completed | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Adakitug diligence evidence.
3. Clinical readouts: what is known
A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 in Advanced Hepatocellular Carcinoma (HCC) Patients
Study: NCT04050462 (CTgov). Phase: Phase 2. Enrollment: 13. Published: 2025-10-16.
ORR = 20 percentage of particpants | ORR = 28.57 percentage of particpants
A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Study: NCT03400332 (CA027-002, CTgov). Phase: Phase 1/2. Enrollment: 281. Published: 2025-06-19.
Number of Participants Experiencing Adverse Events (AEs) - Part 1 = 16 Pts | Number of Participants Experiencing Adverse Events (AEs) - Part 1 = 14 Pts
Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer
Study: NCT03689699 (MAGIC-8, CTgov). Phase: Phase 1/2. Enrollment: 59. Published: 2025-04-29.
Number of Participants With Prostate-specific Antigen (PSA) Recurrence = 8 Pts | Number of Participants With Prostate-specific Antigen (PSA) Recurrence = 6 Pts
121MO - Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: final analysis from the randomized part 2 of the phase 1/2 CA027-002 study
Study: NCT03400332 (CA027-002, ESMO_IO2024). Phase: Phase 2. Enrollment: 122. Published: 2024-12-12.
ORR = 15 % (95%CI, 6.9–25.8) | ORR = 12 % (95%CI, 4.8–22.6)
Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)
Study: ESMO_IO2023. Phase: Phase 2. Enrollment: 36. Published: 2023-12-07.
Time to surgery (TTS) = 34.8 Day
200MO - Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results
Study: NCT03400332 (ESMO_IO2022). Phase: Phase 1/2. Enrollment: 159. Published: 2022-12-08.
PR(pts with melanoma) = 13 % | CR(pts with melanoma) = 1 Pts
A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8).
Study: NCT03689699 (MAGIC-8, ASCO2022). Phase: Phase 1/2. Enrollment: 59. Published: 2022-06-02.
PSA relapse(at 10 months) = 17.39 % | PSA relapse(at 10 months) = 35 %
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Study: NCT02536469 (Pubmed | J Immunother Cancer). Phase: Phase 1. Enrollment: 15. Published: 2019-09-05.
DLT = 0 Pts
Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
Study: NCT02536469 (ASCO2018). Phase: Phase 1. Enrollment: 15. Published: 2018-06-01.
TRAE = no serious treatment-related adverse events (TRAEs) were observed and MTD was not identified through 32mg/kg. TRAEs occurred in 5 pts (33%), and all were Grade 1 except for Grade 2 fatigue, hypophosphatemia and hypersomnia in two patients receiving 32mg/kg
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Adakitug diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Adakitug against approved therapies and clinical competitors in Hepatocellular Carcinoma, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Adakitug diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2012-05-30 | Genmab A/S announced today it has granted an exclusive, worldwide license to its HuMax®-IL8 antibody to Cormorant Pharmaceuticals. | Active | License | Not disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Adakitug diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
